MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562848241299737

Медицинская библиотека · Therapeutic advances in gastroenterology · 2024

Appropriateness of small molecule agents for patients with IBD of childbearing age - a RAND/UCLA appropriateness panel.

Selinger Christian, Laube Robyn, Limdi Jimmy K, Headley Kate, Kent Alexandra, Kok Klaartje, Fraser Aileen, Newman Victoria, Ludlow Helen, Rees Fiona, Sagar Nidhi, Walker Erin

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Many women of childbearing age with inflammatory bowel disease (IBD) require advanced therapies. While biologics are largely low risk during pregnancy, the novel small molecules tofacitinib, filgotinib, upadacitinib and ozanimod (TFUO) have shown concerning teratogenic effects, and decreased fertility in animal studies. Therefore, their use in women of childbearing age needs careful consideration.

DESIGN

RAND/University of California Los Angeles (UCLA) Appropriateness Method (RAM).

OBJECTIVE

To evaluate the appropriateness of TFUO in women of childbearing age.

METHODS

We convened a panel of six gastroenterologists, two IBD nurses, one IBD pharmacist and three expert patients. Following a literature review, 13 statements were drafted and voted upon in 2 rounds.

RESULTS

All 13 statements were deemed appropriate. The panel concluded that women with IBD of childbearing age who wish to commence therapy with TFUO, need to use effective contraception and be counselled regarding the risk in unplanned pregnancies. For women using contraception while on Janus kinase inhibitor (JAKi) therapy, we suggest the preferred use of progesterone-only or non-hormonal long-acting contraception. TFUO are contraindicated during pregnancy and breast feeding. We recommend that women receiving TFUO cease therapy in time to establish clinical remission for at least 3 months prior to conception. Therapies other than TFUO should be considered as first-line therapy in women with IBD of childbearing age, except in select individual circumstances. TFUO may be appropriate for women of childbearing age after failure of, intolerance or contraindications to one biological agent.

CONCLUSION

TFUO should be avoided during pregnancy and breastfeeding, and alternative therapies should be considered as first-line treatments.

SUMMARY: We provide clinical practice recommendations regarding the use of TFUO for IBD in women of childbearing age.

Для цитирования: Selinger Christian, Laube Robyn, Limdi Jimmy K, Headley Kate, Kent Alexandra, Kok Klaartje, Fraser Aileen, Newman Victoria, Ludlow Helen, Rees Fiona, Sagar Nidhi, Walker Erin. Appropriateness of small molecule agents for patients with IBD of childbearing age - a RAND/UCLA appropriateness panel.. Therapeutic advances in gastroenterology. 2024. DOI: 10.1177/17562848241299737.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.